Huaier Granules for Prevention of Recurrence and Metastasis of Colorectal Cancer Patients Following Radical Surgery

Recruiting now

Conditions studied: Colorectal Cancer

In brief

To evaluate the efficacy and safety of Huaier granules for Prevention of Recurrence and Metastasis of colorectal cancer patients following radical surgery

Key facts

Study ID

NCT03349762

Run by

Xi Shan Wang

People needed

3060

Starts

2018-11-02

Expected to finish

2028-06-30

Last updated by the study team

2024-06-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females ages 18-75 years;
• The first time to the therapy of patients who received the radical surgery within two months, Postoperative histopathology confirms the diagnosis of colorectal cancer with stage IIB, IIC and III ( TNM classification)
• ECOG score of 0-2;
• No history of malignant tumors;
• The patients are volunteered for the study, sign informed consent form and cooperate with Investigator to collect data.

You may not qualify if…

• Patients have basic diseases including heart diseases, cerebrovascular disease, lung disease, severe hypertension or diabetes with poor glycemic control;
• confirmed infections after surgery ;
• Patients who have post-surgery complications or who are currently under the influence of the radical surgery for colorectal cancer;
• Being infected with syphilis or with other blood-borne infectious diseases;
• Pregnancy or lactation; or women of childbearing potential not using contraception;
• Patients who have taken Traditional Chinese Medicines with efficacy and indications similar to that of Huaier granule - including, but not limited to, compound Banmao capsule., Huachansu capsule, Kangai Injection and Pingxiao tablets;
• Patients who are suffering from mental illness or Conditions that are considered not suitable for this study investigators.

Where it is running

• The Fourth Hospital of Hebei Medical University — Shijiazhuang, Hebei, China (enrolling)
• The First Clinical Hospital affiliated to Harbin Medical University — Harbin, Heilongjiang, China (enrolling)
• The Second Affiliated Hospital of Harbin Medical University — Harbin, Heilongjiang, China (enrolling)
• Hubei Cancer Hospita — Wuhan, Hubei, China (enrolling)
• Union Hospital Tongji College Huazhong University of Science and Technology — Wuhan, Hubei, China (enrolling)
• Hunan Provincial People's Hospital — Changsha, Hunan, China (enrolling)
• Xiangya Hospital Central South University — Changsha, Hunan, China (enrolling)
• Changzhou No.2 People's Hospital — Changzhou, Jiangsu, China (enrolling)
• The Affiliated Hospital of Xuzhou Medical University — Xuzhou, Jiangsu, China (enrolling)
• Northern Jiangsu People's Hospital — Yangzhou, Jiangsu, China (enrolling)
• Anshan Cancer Hospital — Anshan, Liaoning, China (enrolling)
• Ansteel Group General Hospital — Anshan, Liaoning, China (enrolling)
• The First Affiliated Hospital of Jinzhou Medical University — Jinzhou, Liaoning, China (enrolling)
• Shandong Provincial Hospital — Jinan, Shandong, China (enrolling)
• The Affiliated Hospital of Qingdao University — Qingdao, Shandong, China (enrolling)
• Yantai Yuhuangding Hospital — Yantai, Shandong, China (enrolling)
• Zaozhuang Municipal Hospital — Zaozhuang, Shandong, China (enrolling)
• First Affiliated Hospital of Xi'an Jiaotong University — Xi’an, Shanxi, China (enrolling)
• Tianjin Medical University Cancer Institute and Hospital — Tianjin, Tianjin Municipality, China (enrolling)
• First Affiliated Hospital of Xinjiang Medical University — Ürümqi, Xinjiang, China (enrolling)
• Cancer Hospital Chinese Academy of Medical Sciences — Beijing, China (enrolling)
• Fudan University Shanghai Cancer Center — Shanghai, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.